Diabetes Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2034

Diabetes Diagnostics Market Summary

Overview:

• The Diabetes Diagnostics market is estimated at USD 22 billion in 2025 and is projected to reach USD 42 billion by 2034. Growth is anchored in the rising global prevalence of diabetes and prediabetes, the rapid adoption of continuous glucose monitoring, and the expansion of screening and monitoring across home and clinical settings.
• The global Diabetes Diagnostics market is growing at a CAGR of 7.5% during the forecast period from 2026 to 2034.
• By product, the continuous glucose monitoring systems segment dominated the Diabetes Diagnostics market with a 51% share in 2025.
• By test type, the blood glucose monitoring segment dominated the Diabetes Diagnostics market with a share of 64% in 2025.
• By end-user, the homecare and self-testing segment dominated the Diabetes Diagnostics market with a share of 55% in 2025.
• North America dominated the global Diabetes Diagnostics market revenue with a share of 40% in 2025, representing the highest regional market share globally.

Diabetes diagnostics encompasses the devices, systems, and tests used to screen for, diagnose, and monitor diabetes mellitus and prediabetes by measuring blood glucose, glycated hemoglobin, and related markers. The category spans self-monitoring blood glucose systems, comprising glucometers, test strips, and lancets; continuous glucose monitoring systems, comprising sensors, transmitters, and readers or smartphone applications; glycated hemoglobin testing systems used in laboratories and at the point of care; and urine glucose and ketone testing. Leading products include Abbott's FreeStyle Libre family and Lingo and Libre Rio over-the-counter sensors, Dexcom's G7 and Stelo over-the-counter systems, Medtronic's Guardian and Simplera sensors, Roche's Accu-Chek meters and cobas and other laboratory analyzers, LifeScan's OneTouch meters, Ascensia's Contour meters, and dedicated glycated hemoglobin analyzers from Bio-Rad, Tosoh, and others. Diabetes diagnostics is used across type 1, type 2, and gestational diabetes and prediabetes, in home, hospital, clinic, and laboratory settings. Over the past decade, the field has shifted from episodic finger-stick testing toward continuous, connected, and increasingly consumer-accessible glucose monitoring, integrated with automated insulin delivery and digital health platforms. Driven by the escalating global burden of diabetes, the rise of continuous glucose monitoring, and expanding screening and reimbursement, diabetes diagnostics has become one of the largest and most dynamic segments of in vitro and point-of-care diagnostics worldwide.

Diabetes Diagnostics Market Key Growth Drivers

• The rising global prevalence of diabetes is a primary driver, with the International Diabetes Federation reporting 589 million adults living with diabetes in 2024 and projecting 853 million by 2050, expanding the population requiring diagnosis and monitoring.
• The rapid adoption of continuous glucose monitoring, led by Abbott's FreeStyle Libre and Dexcom systems, is expanding the market and shifting value toward sensor-based monitoring.
• The high prevalence of prediabetes and undiagnosed diabetes is driving demand for screening and early diagnosis across health systems.
• Technological advances, including smaller and more accurate sensors, over-the-counter continuous glucose monitors, and integration with automated insulin delivery and digital health, are broadening adoption.
• The rising burden of obesity and sedentary lifestyles is increasing the incidence of type 2 diabetes and the associated demand for diagnostics.
• Expanding reimbursement for continuous glucose monitoring and growing healthcare access in emerging markets are broadening the addressable population.
• The convergence of rising diabetes burden, continuous glucose monitoring adoption, and expanding screening is expected to sustain strong growth in the global Diabetes Diagnostics market through 2034.

Key Companies in Diabetes Diagnostics Market

The competitive landscape is led by the following active developers and manufacturers of diabetes diagnostics devices, systems, and tests:

• Abbott Laboratories
• Dexcom, Inc.
• F. Hoffmann-La Roche Ltd
• Medtronic plc
• LifeScan, Inc.
• Ascensia Diabetes Care Holdings AG
• Senseonics Holdings, Inc.
• ARKRAY, Inc.
• Bio-Rad Laboratories, Inc.
• Trividia Health, Inc.

Factors Contributing to the Growth of the Diabetes Diagnostics Market

Market Drivers

Rising Global Prevalence of Diabetes

The escalating global prevalence of diabetes is the foundational driver of diabetes diagnostics demand. According to the International Diabetes Federation, approximately 589 million adults aged 20 to 79 were living with diabetes in 2024, and the figure is projected to reach 853 million by 2050, while a large proportion of cases remain undiagnosed. Every person living with diabetes requires ongoing glucose monitoring and periodic glycated hemoglobin testing, generating a vast and recurring base of demand for meters, strips, sensors, and laboratory tests. Type 2 diabetes, driven by aging, obesity, and lifestyle factors, accounts for the large majority of cases and continues to grow, and gestational diabetes and prediabetes add further demand. The chronic, lifelong nature of diabetes ensures sustained, repeat testing throughout each patient's life. As diabetes prevalence continues to rise worldwide and diagnosis rates improve, demand for diabetes diagnostics continues to grow, reinforcing sustained market growth throughout the forecast period.

Rapid Adoption of Continuous Glucose Monitoring

The rapid adoption of continuous glucose monitoring is a defining driver of the diabetes diagnostics market. Continuous glucose monitoring systems, led by Abbott's FreeStyle Libre family and Dexcom's G7, provide real-time or intermittently scanned glucose readings from a wearable sensor, replacing or supplementing finger-stick testing and improving glycemic control. Adoption has expanded rapidly among people with type 1 and, increasingly, type 2 diabetes, supported by clinical evidence, expanding reimbursement, and integration with automated insulin delivery systems. Continuous glucose monitoring commands substantially higher value per user than conventional self-monitoring and has become the primary engine of market growth, with Abbott and Dexcom generating multibillion-dollar sensor franchises. The launch of over-the-counter continuous glucose monitors, including Dexcom's Stelo and Abbott's Lingo and Libre Rio, is extending the technology to people with type 2 diabetes not on insulin and to health-conscious consumers. As continuous glucose monitoring continues to displace finger-stick testing and reach new populations, its adoption is expected to be the leading driver of market growth across the forecast period.

Market Restraints

Despite strong momentum, the Diabetes Diagnostics market faces material constraints. The high cost of continuous glucose monitoring systems and their recurring sensors limits adoption, particularly among people with type 2 diabetes not on insulin and in resource-limited settings, and out-of-pocket costs remain a barrier where reimbursement is limited. Reimbursement variability is a significant challenge, as coverage for continuous glucose monitoring differs across payers, countries, and patient categories, and restrictive criteria can limit access. The self-monitoring blood glucose segment faces price pressure and commoditization, as test strips are low-margin and increasingly competitive, and the shift to continuous glucose monitoring erodes strip volumes. Accuracy, calibration, and reliability considerations, including sensor variability, warm-up periods, and interference, can affect clinical confidence and require oversight. Regulatory requirements for diagnostic and monitoring devices, including Food and Drug Administration clearance and the European In Vitro Diagnostic Regulation, add cost and complexity to development and market entry. Intense competition among a few large players compresses prices and margins, and the need for patient education and adherence support adds operational demands. Finally, uneven infrastructure, affordability constraints, and supply limitations in emerging markets can restrict access and adoption across parts of the forecast period.

Diabetes Diagnostics Market Segment Analysis

The Diabetes Diagnostics Market is segmented by Product (Self-Monitoring Blood Glucose Systems, Continuous Glucose Monitoring Systems, HbA1c Testing Systems, Urinalysis and Ketone Testing, Others), Test Type (Blood Glucose Monitoring, Glycated Hemoglobin (HbA1c) Testing, Oral Glucose Tolerance Test, Fasting Plasma Glucose, Urine Glucose and Ketone Testing), End-User (Homecare and Self-Testing, Hospitals and Clinics, Diagnostic Laboratories, Others), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Product

Dominant Subsegment: Continuous Glucose Monitoring Systems.

The continuous glucose monitoring systems segment accounted for 51% of the Diabetes Diagnostics market in 2025. Continuous glucose monitoring dominates because sensor-based monitoring has become the standard of care for type 1 diabetes and is rapidly expanding in type 2 diabetes, commanding substantially higher value per user than conventional testing. Abbott's FreeStyle Libre family and Dexcom's G7 have built multibillion-dollar franchises, and Medtronic's Guardian and Simplera sensors and Senseonics' Eversense implantable system add further offerings. Continuous glucose monitoring provides real-time or intermittently scanned glucose data, alerts, and trends, improves glycemic control, and integrates with automated insulin delivery, and the launch of over-the-counter systems such as Dexcom's Stelo and Abbott's Lingo and Libre Rio is extending the technology to new populations. The self-monitoring blood glucose systems segment, comprising glucometers, test strips, and lancets from LifeScan, Roche, Ascensia, and others, remains a very large segment by volume and installed base but faces price pressure and gradual displacement by continuous monitoring. Glycated hemoglobin testing systems, urinalysis and ketone testing, and other products complete the market. Nonetheless, the higher value, rapid adoption, and clinical superiority of continuous glucose monitoring secure the segment's leadership across the forecast period.

By Test Type

Dominant Subsegment: Blood Glucose Monitoring.

The blood glucose monitoring segment accounted for 64% of the Diabetes Diagnostics market in 2025. Blood glucose monitoring, encompassing both self-monitoring blood glucose testing and continuous glucose monitoring, dominates because ongoing glucose measurement is the core, daily activity of diabetes management for hundreds of millions of people. Every person with insulin-treated diabetes, and increasingly many with non-insulin-treated type 2 diabetes, monitors glucose frequently, generating enormous, recurring demand for meters, strips, and sensors. The rapid growth of continuous glucose monitoring, alongside the large installed base of self-monitoring, sustains the leading share of this test type. Glycated hemoglobin testing represents the second-largest test type, providing a standardized measure of average glycemic control used for diagnosis and periodic monitoring in laboratories and at the point of care. Oral glucose tolerance testing and fasting plasma glucose testing are important diagnostic tests, particularly for gestational diabetes and screening, and urine glucose and ketone testing adds further use, including in ketoacidosis risk assessment. Nonetheless, the daily, lifelong nature and vast scale of glucose monitoring secure the leadership of the blood glucose monitoring segment across the forecast period.

Diabetes Diagnostics Market Region Analysis

Dominant Region: North America

North America accounted for 40% of the global Diabetes Diagnostics market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high prevalence of diabetes and prediabetes, rapid adoption of continuous glucose monitoring, broad reimbursement, and the presence of leading manufacturers. The United States leads on the strength of high diabetes prevalence, the fastest and broadest adoption of continuous glucose monitoring, expanding Medicare and payer coverage, and the presence of major players including Abbott, Dexcom, and Medtronic. Disease burden is substantial, with a large diabetic and prediabetic population and rising obesity. The regulatory environment is supportive, with the Food and Drug Administration providing clearance pathways and having cleared the first over-the-counter continuous glucose monitors, and reimbursement for continuous glucose monitoring has expanded significantly. Strong distribution, retail pharmacy channels, and digital health integration further reinforce the market. This combination of disease burden, adoption, and reimbursement reinforces North America's leadership in the global market.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Diabetes Diagnostics market. The region's elevated CAGR is driven by very large and rapidly growing diabetic populations, rising obesity and urbanization, expanding healthcare access, and growing adoption of glucose monitoring across China, India, Japan, South Korea, and Southeast Asia. China and India together account for an enormous share of the global diabetic population, and rising diagnosis rates and healthcare investment are expanding demand for diagnostics. Growing incomes, insurance coverage, and awareness are improving access to glucose meters and, increasingly, continuous glucose monitoring, and both multinational and fast-growing regional manufacturers are expanding lower-cost offerings and local presence. Government diabetes screening and management initiatives further support growth. The combination of large and growing patient populations, rising prevalence, expanding access, and increasing adoption of continuous monitoring positions Asia-Pacific as the highest-growth region over the forecast period.

Regional Commentary

North America

North America accounted for 40% of the global Diabetes Diagnostics market revenue in 2025. The United States dominates the region on the strength of high diabetes prevalence, the broadest adoption of continuous glucose monitoring, expanding reimbursement, and the presence of leading manufacturers, while Canada contributes through public coverage and Mexico expands access within its large and growing diabetic population.

Europe

Europe represents the second-largest regional market, led by Germany, the United Kingdom, and France. Growth is supported by a high diabetes burden, broad reimbursement for continuous glucose monitoring, and the presence of major manufacturers such as Roche and Ascensia, while the European In Vitro Diagnostic Regulation shapes product requirements and market access across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by very large and rapidly growing diabetic populations, rising obesity and urbanization, expanding access, and increasing adoption of glucose monitoring across China, India, Japan, South Korea, and Southeast Asia. Expanding domestic manufacturing and lower-cost offerings are broadening access.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. A rising burden of diabetes, improving healthcare access, and expanding availability of glucose monitoring and diagnostic testing are broadening adoption, while the Middle East in particular has among the highest regional diabetes prevalence rates globally.

Diabetes Diagnostics Market Competitive Landscape

The Diabetes Diagnostics market is classified as Moderately Concentrated. A group of large medical technology and diagnostics companies holds the majority of revenue, led by Abbott and Dexcom in continuous glucose monitoring and Roche, LifeScan, and Ascensia in self-monitoring blood glucose, while Medtronic, Senseonics, ARKRAY, Bio-Rad, and Trividia hold significant positions, and a field of regional and specialized players competes across the market. The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with continuous glucose monitoring highly concentrated among a few leaders and self-monitoring blood glucose more fragmented.
• Leading players: Abbott and Dexcom lead in continuous glucose monitoring, while Roche, LifeScan, and Ascensia lead in self-monitoring blood glucose, with Medtronic, Senseonics, ARKRAY, Bio-Rad, and Trividia holding significant positions.
• Geographic reach: Leaders operate global commercial, manufacturing, and distribution networks, with strong positions across North America, Europe, and Asia-Pacific.
• Product portfolio strength: Top players hold broad portfolios spanning continuous glucose monitoring, self-monitoring blood glucose, glycated hemoglobin testing, and connected digital platforms.
• Pipeline strength: Deep pipelines in next-generation continuous glucose monitoring sensors, over-the-counter monitors, integration with automated insulin delivery, and digital health.
• Strategic partnerships: Extensive collaborations with insulin pump and automated insulin delivery companies, digital health platforms, and pharmacies shape the competitive landscape.
• M&A activity: Continued acquisitions and partnerships to build continuous glucose monitoring, digital, and connected diabetes management capabilities.
• Manufacturing capabilities: Large-scale sensor and strip manufacturing capacity is a key competitive strength and barrier to entry.
• Innovation focus: Smaller and more accurate sensors, over-the-counter continuous glucose monitoring, automated insulin delivery integration, connectivity, and digital health.

Diabetes Diagnostics Market Recent Developmental Activities

In 2024, the Food and Drug Administration cleared the first over-the-counter continuous glucose monitors, Dexcom's Stelo and Abbott's Lingo and Libre Rio, enabling non-prescription purchase. Strategic significance: Opens a new consumer channel and extends continuous glucose monitoring to people with type 2 diabetes not on insulin and health-conscious users.

Diabetes Diagnostics Market Segmentation

Diabetes Diagnostics Market by Product

• Self-Monitoring Blood Glucose Systems
• Continuous Glucose Monitoring Systems
• HbA1c Testing Systems
• Urinalysis and Ketone Testing
• Others

Diabetes Diagnostics Market by Test Type

• Blood Glucose Monitoring
• Glycated Hemoglobin (HbA1c) Testing
• Oral Glucose Tolerance Test
• Fasting Plasma Glucose
• Urine Glucose and Ketone Testing

Diabetes Diagnostics Market by End-User

• Homecare and Self-Testing
• Hospitals and Clinics
• Diagnostic Laboratories
• Others

Diabetes Diagnostics Market by Geography

• North America Diabetes Diagnostics Market
• United States Diabetes Diagnostics Market Size in USD million (2023-2034)
• Canada Diabetes Diagnostics Market Size in USD million (2023-2034)
• Mexico Diabetes Diagnostics Market Size in USD million (2023-2034)
• Europe Diabetes Diagnostics Market
• Germany Diabetes Diagnostics Market Size in USD million (2023-2034)
• United Kingdom Diabetes Diagnostics Market Size in USD million (2023-2034)
• France Diabetes Diagnostics Market Size in USD million (2023-2034)
• Italy Diabetes Diagnostics Market Size in USD million (2023-2034)
• Spain Diabetes Diagnostics Market Size in USD million (2023-2034)
• Rest of Europe Diabetes Diagnostics Market Size in USD million (2023-2034)
• Asia-Pacific Diabetes Diagnostics Market
• China Diabetes Diagnostics Market Size in USD million (2023-2034)
• Japan Diabetes Diagnostics Market Size in USD million (2023-2034)
• India Diabetes Diagnostics Market Size in USD million (2023-2034)
• Australia Diabetes Diagnostics Market Size in USD million (2023-2034)
• South Korea Diabetes Diagnostics Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Diabetes Diagnostics Market Size in USD million (2023-2034)
• Rest of the World (RoW) Diabetes Diagnostics Market
• Middle East Diabetes Diagnostics Market Size in USD million (2023-2034)
• Africa Diabetes Diagnostics Market Size in USD million (2023-2034)
• South America Diabetes Diagnostics Market Size in USD million (2023-2034)

Key Takeaways from the Diabetes Diagnostics Market Report Study

• Market size analysis for the current diabetes diagnostics market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global diabetes diagnostics market.
• Various opportunities available for competitors in the diabetes diagnostics market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current diabetes diagnostics market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for diabetes diagnostics market growth in the future?

Target audience that can benefit from this diabetes diagnostics market report study

• Diabetes Diagnostics product providers
• Research organizations and consulting companies
• Diabetes Diagnostics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in diabetes diagnostics products
• Various end-users who want to know more about the diabetes diagnostics market and the latest technological developments in the diabetes diagnostics market.

Frequently Asked Questions:

Q1. What is the growth rate of the Diabetes Diagnostics market?

The Diabetes Diagnostics market is projected to expand at a CAGR of 7.5% during the forecast period of 2026-2034.

Q2. What is the market size of the Diabetes Diagnostics market?

The Diabetes Diagnostics market is estimated at USD 22 billion in 2025 and is projected to reach USD 42 billion by 2034.

Q3. Which region dominates the Diabetes Diagnostics market?

North America dominated the Diabetes Diagnostics market with a 40% share of global revenue in 2025, supported by high diabetes prevalence, the broadest adoption of continuous glucose monitoring, expanding reimbursement, supportive FDA pathways, and the presence of leading manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Diabetes Diagnostics market?

The principal drivers are the rising global prevalence of diabetes, projected by the International Diabetes Federation to increase from 589 million adults in 2024 to 853 million by 2050; the rapid adoption of continuous glucose monitoring; the high prevalence of prediabetes and undiagnosed diabetes; and technological advancement in monitoring and connectivity, reinforced by rising obesity and expanding reimbursement and emerging-market access.

Q5. Who are the major players in the Diabetes Diagnostics market?

The major players include Abbott Laboratories, Dexcom, Inc., F. Hoffmann-La Roche Ltd, Medtronic plc, LifeScan, Inc., Ascensia Diabetes Care Holdings AG, Senseonics Holdings, Inc., ARKRAY, Inc., Bio-Rad Laboratories, Inc., and Trividia Health, Inc., among other active manufacturers profiled in the Competitive Landscape section. Abbott and Dexcom lead in continuous glucose monitoring, while Roche, LifeScan, and Ascensia lead in self-monitoring blood glucose.